James Crowe
Faculty Member
Last active: 3/31/2019

  1. Challenges and opportunities in developing respiratory syncytial virus therapeutics. Simões EA, DeVincenzo JP, Boeckh M, Bont L, Crowe JE, Griffiths P, Hayden FG, Hodinka RL, Smyth RL, Spencer K, Thirstrup S, Walsh EE, Whitley RJ (2015) J Infect Dis : S1-S20
    › Primary publication · 25713060 (PubMed) · PMC4345819 (PubMed Central)
  2. Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress. Fox JM, Long F, Edeling MA, Lin H, van Duijl-Richter MKS, Fong RH, Kahle KM, Smit JM, Jin J, Simmons G, Doranz BJ, Crowe JE, Fremont DH, Rossmann MG, Diamond MS (2015) Cell 163(5): 1095-1107
    › Primary publication · 26553503 (PubMed) · PMC4659373 (PubMed Central)
  3. Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein. Chukwuma VU, Hicar MD, Chen X, Nicholas KJ, Joyner A, Kalams SA, Landucci G, Forthal DN, Spearman PW, Crowe JE (2015) PLoS One 10(7): e0133509
    › Primary publication · 26226263 (PubMed) · PMC4520566 (PubMed Central)
  4. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sariol CA, Crowe JE, de Silva AM, Baric RS (2015) MBio 6(5): e01461-15
    › Primary publication · 26463165 (PubMed) · PMC4620467 (PubMed Central)
  5. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Fibriansah G, Tan JL, Smith SA, de Alwis R, Ng TS, Kostyuchenko VA, Jadi RS, Kukkaro P, de Silva AM, Crowe JE, Lok SM (2015) Nat Commun : 6341
    › Primary publication · 25698059 (PubMed) · PMC4346626 (PubMed Central)
  6. Tissue-specific expressed antibody variable gene repertoires. Briney BS, Willis JR, Finn JA, McKinney BA, Crowe JE (2014) PLoS One 9(6): e100839
    › Primary publication · 24956460 (PubMed) · PMC4067404 (PubMed Central)
  7. STAT4 deficiency fails to induce lung Th2 or Th17 immunity following primary or secondary respiratory syncytial virus (RSV) challenge but enhances the lung RSV-specific CD8+ T cell immune response to secondary challenge. Dulek DE, Newcomb DC, Toki S, Goliniewska K, Cephus J, Reiss S, Bates JT, Crowe JE, Boyd KL, Moore ML, Zhou W, Peebles RS (2014) J Virol 88(17): 9655-72
    › Primary publication · 24920804 (PubMed) · PMC4136353 (PubMed Central)
  8. Proof of principle for epitope-focused vaccine design. Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, Rupert P, Correnti C, Kalyuzhniy O, Vittal V, Connell MJ, Stevens E, Schroeter A, Chen M, Macpherson S, Serra AM, Adachi Y, Holmes MA, Li Y, Klevit RE, Graham BS, Wyatt RT, Baker D, Strong RK, Crowe JE, Johnson PR, Schief WR (2014) Nature 507(7491): 201-6
    › Primary publication · 24499818 (PubMed) · PMC4260937 (PubMed Central)
  9. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE (2014) J Virol 88(21): 12233-41
    › Primary publication · 25100837 (PubMed) · PMC4248927 (PubMed Central)
  10. Intracellular neutralization of a virus using a cell-penetrating molecular transporter. Sapparapu G, Sims AL, Aiyegbo MS, Shaikh FY, Harth EM, Crowe JE (2014) Nanomedicine (Lond) 9(11): 1613-24
    › Primary publication · 24195674 (PubMed)